The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

Believes Proposed Offer of $12.50 / Share Significantly Undervalues the Company and Does Not Adequately Compensate Shareholders for Exceptional Growth Ahead Does Not Intend to Vote For the Deal and ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...

Detailed price information for Avid Bioservices Inc (CDMO-Q) from The Globe and Mail including charting and trades.

GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at ...

RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company ...

Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.

Avid Bioservices (NASDAQ:CDMO) has agreed to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at around $1.1B.

The $12.50-per-share takeover has been approved by Avid's board and is scheduled to close in the first quarter of 2025, ...

Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization, ...